Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

August 15, 2025

Study Completion Date

August 15, 2025

Conditions

GlioblastomaRecurrent Glioblastoma

Interventions

DRUG

Verteporfin

Given IV

Trial Locations (1)

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER